Intervention Review

Rivastigmine for Alzheimer's disease

  1. Jacqueline Birks1,*,
  2. John Grimley Evans2,
  3. Vasso Iakovidou3,
  4. Magda Tsolaki4

Editorial Group: Cochrane Dementia and Cognitive Improvement Group

Published Online: 15 APR 2009

Assessed as up-to-date: 8 SEP 2008

DOI: 10.1002/14651858.CD001191.pub2

How to Cite

Birks J, Grimley Evans J, Iakovidou V, Tsolaki M. Rivastigmine for Alzheimer's disease. Cochrane Database of Systematic Reviews 2009, Issue 2. Art. No.: CD001191. DOI: 10.1002/14651858.CD001191.pub2.

Author Information

  1. 1

    University of Oxford, Centre for Statistics in Medicine, Oxford, UK

  2. 2

    University of Oxford, Division of Clinical Geratology, Nuffield Department of Clinical Medicine, Oxford, UK

  3. 3

    Thessaloniki, Makedonia, Greece

  4. 4

    Aristotle University of Thessaloniki, 3rd Neurology Department, Thessaloniki, Macedonia, Greece

*Jacqueline Birks, Centre for Statistics in Medicine, University of Oxford, Wolfson College, Linton Road, Oxford, OX2 6UD, UK.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 15 APR 2009


Options for accessing this content:

  • If you have access to this content through a society membership, please first log in to your society website.
  • Login via other institutional login options
  • You can purchase online access to this Article for a 24-hour period (price varies by title)
    • If you already have a Wiley Online Library or Wiley InterScience user account: login above and proceed to purchase the article.
    • New Users: Please register, then proceed to purchase the article.

Login via OpenAthens


Search for your institution's name below to login via Shibboleth.

Please register to:

  • Save publications, articles and searches
  • Get email alerts
  • Get all the benefits mentioned below!

Register now >

Patient Access

Patients and/or caregivers may access this content for use in relation to their own personal healthcare or that of a family member only. Terms and conditions will apply.